What the FDA labels say about taking them together
Dabigatran and glecaprevir/pibrentasvir
Glecaprevir/pibrentasvir's FDA label of June 25, 2025 names dabigatran in its drug interactions section; the dabigatran labels PlainMeds reads (2) do not name glecaprevir/pibrentasvir. The glecaprevir/pibrentasvir label: “If MAVYRET and dabigatran etexilate are coadministered, refer to the dabigatran etexilate prescribing information for dabigatran etexilate dose modifications in combination with P-gp inhibitors in the setting of renal …”
Check it at the source: the dabigatran FDA label on DailyMed (effective June 25, 2025, Boehringer Ingelheim Pharmaceuticals Inc.); the glecaprevir/pibrentasvir FDA label on DailyMed (effective June 25, 2025, AbbVie Inc.).
What does the dabigatran label say about glecaprevir/pibrentasvir?
Dabigatran's label (effective June 25, 2025) and its 1 other brand-application label do not name glecaprevir/pibrentasvir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Pradaxa), Boehringer Ingelheim Pharmaceuticals Inc., effective June 25, 2025 (SPL set ba74e3cd-b06f-4145-b284-5fd6b84ff3c9), via openFDA; the full label on DailyMed
What does the glecaprevir/pibrentasvir label say about dabigatran?
Glecaprevir/pibrentasvir label, drug interactionsConcomitant Drug Class/Drug Name: Dabigatran etexilate; Effect on Concentration: ↑ dabigatran; Clinical Comments: If MAVYRET and dabigatran etexilate are coadministered, refer to the dabigatran etexilate prescribing information for dabigatran etexilate dose modifications in combination with P-gp inhibitors in the setting of renal impairment.
Source: FDA drug label (Mavyret), AbbVie Inc., effective June 25, 2025 (SPL set 7bf99777-0401-9095-8645-16c6e907fcc0), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dabigatran | Glecaprevir/pibrentasvir | |
|---|---|---|
| Labeled for | Atrial fibrillation, Blood clots (DVT and PE), Stroke prevention | Hepatitis C |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.795 per capsule 150 mg capsule | $152.98 per tablet 100-40 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once